12:00 AM
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

House dust mites sublingual immunotherapy tablet: Phase II data

The dose-ranging, double-blind, Canadian Phase II VO67.10 trial in 355 adults with house dust mite allergic rhinitis showed that the once-daily 500 IR dose of Stallergenes' house dust mites sublingual immunotherapy tablet met the primary endpoint of reducing RTSS from...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >